Canada· CA-DIN-02286769
WILATE
A von willebrand-faktor und faktor viii in kombination product containing antihemophilic factor (human) + von willebrand factor (human) + human plasma proteins, registered in Canada by OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H. The same ATC class is registered in 11 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Von willebrand-faktor und faktor viii in kombination is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BD06 (von willebrand-faktor und faktor viii in kombination), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 7 of them publish a price we can compare per daily dose
Von willebrand-faktor und faktor viii in kombination · ATC B02BD06
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- ANTIHEMOPHILIC FACTOR (HUMAN) + VON WILLEBRAND FACTOR (HUMAN) + HUMAN PLASMA PROTEINS
- Manufacturer
- OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H
- Country
- Canada (CA)
- ATC code
- B02BD06
- ATC class
- von Willebrand-Faktor und Faktor VIII in Kombination
- Defined daily dose
- 1 TSD, E
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under B02BD06
Von willebrand-faktor und faktor viii in kombination, as other registers publish it.
- PolandFANHDIInstituto Grifols S.A.
- CzechiaFANHDIInstituto Grifols, S.A., Barcelona
- CzechiaFANHDIInstituto Grifols, S.A., Barcelona
- PolandFANHDIInstituto Grifols S.A.
- PolandFANHDIInstituto Grifols S.A.
- CzechiaFANHDIInstituto Grifols, S.A., Barcelona
- CzechiaFANHDIInstituto Grifols, S.A., Barcelona
- FinlandHaemateCSL Behring GmbH
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/48677103-9b7b-47c3-a0c0-a259f8ba8a90 GET /v1/drugs/48677103-9b7b-47c3-a0c0-a259f8ba8a90?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02286769",
"form": "POWDER FOR SOLUTION",
"class": "Human",
"routes": [
"INTRAVENOUS"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "B02BD06",
"schedule": [
"Schedule D"
],
"drug_code": "77222",
"strengths": [
"1000 UNIT",
"15 MG"
],
"ahfs_class": null,
"substances": [
"ANTIHEMOPHILIC FACTOR (HUMAN)",
"VON WILLEBRAND FACTOR (HUMAN)",
"HUMAN PLASMA PROTEINS"
],
"product_categorization": null
}See everything about von willebrand-faktor und faktor viii in kombination.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.